WO2020001152A1 - Composés tricycliques - Google Patents

Composés tricycliques Download PDF

Info

Publication number
WO2020001152A1
WO2020001152A1 PCT/CN2019/084601 CN2019084601W WO2020001152A1 WO 2020001152 A1 WO2020001152 A1 WO 2020001152A1 CN 2019084601 W CN2019084601 W CN 2019084601W WO 2020001152 A1 WO2020001152 A1 WO 2020001152A1
Authority
WO
WIPO (PCT)
Prior art keywords
occurrence
alkyl
deuterium
substituents
methyl
Prior art date
Application number
PCT/CN2019/084601
Other languages
English (en)
Inventor
Haiquan Fang
Mingming Chen
Guiqun YANG
Yuelei DU
Yanping Wang
Tong Wu
Qinglong Li
Lei Zhang
Shaojing Hu
Original Assignee
Jacobio-Beta Pharmaceuticals Co., Ltd.
Jacobio Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG11202012819YA priority Critical patent/SG11202012819YA/en
Priority to KR1020217002239A priority patent/KR102600391B1/ko
Priority to CA3104927A priority patent/CA3104927C/fr
Priority to EP19826294.1A priority patent/EP3814352A4/fr
Priority to JP2020572516A priority patent/JP7168245B2/ja
Priority to EA202190103A priority patent/EA202190103A1/ru
Priority to CN201980041760.8A priority patent/CN112513041B/zh
Priority to AU2019295983A priority patent/AU2019295983B2/en
Application filed by Jacobio-Beta Pharmaceuticals Co., Ltd., Jacobio Pharmaceuticals Co., Ltd. filed Critical Jacobio-Beta Pharmaceuticals Co., Ltd.
Priority to BR112020026337-0A priority patent/BR112020026337A2/pt
Priority to CN202210507765.9A priority patent/CN115109061A/zh
Priority to MX2020014111A priority patent/MX2020014111A/es
Publication of WO2020001152A1 publication Critical patent/WO2020001152A1/fr
Priority to PH12020552210A priority patent/PH12020552210A1/en
Priority to US17/129,983 priority patent/US20210179617A1/en
Priority to ZA2021/00237A priority patent/ZA202100237B/en
Priority to AU2021290208A priority patent/AU2021290208B2/en
Priority to US17/561,381 priority patent/US11466005B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • This invention relates to certain novel tricyclic compounds (Formula I) as bromodomain and extra-terminal (BET) inhibitors which are shown as Formula I, their synthesis and their use for treating diseases. More particularly, this invention is directed to fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.
  • Formula I novel tricyclic compounds
  • BET extra-terminal
  • Histone modification is a process related to the post-translational covalent modification of histone proteins that markedly influences the ability of associated DNA to be transcribed.
  • Lysine acetylation is a post-translational modification with broad relevance to cellular signaling and disease biology.
  • Enzymes that regulate lysine acetylation in histones are termed as ‘writers’ or histone acetyltransferaes (HATs) , and that regulate lysine deacetylation in histone as ‘erasers’ or histone deacetylases (HDACs) .
  • Bromodomains (BRDs) ‘readers’ of epigenetic marks, specifically recognize ⁇ -N-acetyl lysine (Kac) residues on histones tails.
  • BRD is a conserved 110 amino acid structure motif composed of four ⁇ -helices ( ⁇ Z, ⁇ A, ⁇ B, and ⁇ C) that comprise a left-handed bundle (S. Mujtaba, L. Zeng, M.M. Zhou, Oncogene, 2007 (26) , 5521-5527) .
  • the ⁇ -helices are connected together by two loop regions (ZA and BC) and form a surface that interacts with acetylated lysines in nucleosomal histones (C. Dhalluin, J.E. Carlson, L. Zeng et al, Nature, 1999 (399) , 491-496) .
  • bromodomain containing proteins from humans which across eight families based on structure/sequence similarity.
  • bromodomain and extra-terminal domain recognize acetylated lysine residues in histones H3 and H4.
  • BET family containing BRD2, BRD3, BRD4 and BRDT four members, share two N-terminal bromodomains and extra C-terminal domain (ET) exhibiting high levels of sequence conservation.
  • BRD2 and BRD3 associate with histones along actively transcribed genes and maybe involved in facilitating transcriptional elongation (Leroy et al., Mol. Cell 2008 30 (1) , 51-60) .
  • BRD4 appears to be involved in the recruitment of the positive transcriptional elongation factor complex (pTEF-I3) , which plays an essential role in the regulation of transcription by RNA polymerase and increased transcriptional output (Hargreaves et al., Cell, 2009 138 (1) : 1294145) .
  • pTEF-I3 positive transcriptional elongation factor complex
  • BRDT expression is normally testis-specific (M.H. Jones et al, Genomics, 1997 (45) , 529-534) and BRDT is essential for spermatogenesis (E. Shang et al, Development, 2007 (134) , 3507-3515) .
  • BET proteins Binding of BET proteins to acetylated histones leads to recruiting BET proteins to the enhancer and promoter regions of genes for active transcription. By that, they interact with coactivators, repressors, transcription factors and transcriptional machinery to form protein complexs and influence target gene transcription (A. Dey et al, Proc. Natl. Acad. Sci, U.S.A. 2003 (100) , 8758-8763) .
  • BET proteins although having a similar structure and usually enhancing transcription, regulate different processes based on their binding partners, which are often tissue-specific.
  • BET proteins primarily mediate their effects in disease pathogenesis and progression mainly by localizing to super-enhancers (SEs) at pathology-associated genes and driving their expression (M.A. Dawson et al, Nature, 2011 (478) , 529-533; B. Chapuy et al, Cancer Cell, 2013 (24) , 777-790) .
  • SEs are enriched at oncogenes like MYC, RUNX1, FOSL2, CCND1, MCL1, and BCL2L1 (B. Chapuy et al, Cancer Cell, 2013 (24) , 777-790; J. Loven, Cell, 2013 (153) , 320-334; W.A.
  • Small molecule BET inhibitors that are reported in clinical development include RVX-208, GSK-525762A, GSK2820151, OTX-015, CPI-0610, TEN-010/RO6870810, ABBV-075/ABBV-744, BI 894999, BMS-986158, INCB054329/INCB057643, ZEN-3694 GS-5829, AZD5153 as well as an inhibitor from Celgene.
  • BET inhibitors that have improved properties over existing BET inhibitors, for example, improved potency, safety, tolerability, pharmacokinetics and/or pharmocodynamics.
  • X 1 is selected from O, S, SO, SO 2 or NR 1 ;
  • R 1 is selected from hydrogen; deuterium; -CN; -SOR 11 ; -SO 2 R 11 ; -SO 2 NR 11 R 12 ; -C 1-6 alkyl; -C 2-6 alkenyl; -C 2-6 alkynyl; carboxyl; -NO 2 ; -COOR 11 ; -COR 11 ; -CONR 11 R 12 ; -POR 11 R 12 ; -C 5-6 aryl; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; -C 3-8 heterocyclic containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, ox
  • Each of R 11 and R 12 at each occurrence is independently selected from hydrogen; deuterium; -OH; -NH 2 ; -CN; -C 1-6 alkyl; -C 1-6 alkoxy; -C 5-6 aryl; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; -C 1-6 alkylene-C 3-8 carbocyclic; or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -C 1-6 alkyl, -C 1-6 alkoxy, carboxyl, -SO 2 (C 1-6 alkyl) or -C 3-8 carb
  • each of the heterocyclic ring at each occurrence can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium; halogen; -OH; oxo; -CN; -C 1-6 alkyl; -C 1-6 alkoxy; -SO 2 (C 1-6 alkyl) ; -CON (C 1-6 alkyl) 2 ; -SO 2 N (C 1-6 alkyl) 2 ; -NH 2 ; -NH (C 1-6 alkyl) ; -N (C 1-6 alkyl) 2 ; -C 3-6 heterocyclic containing 1 or 2 heteroatoms selected from N, O or S; or
  • Each of R 13 and R 14 at each occurrence is independently selected from hydrogen, deuterium, halogen, -NH 2 , -C 1-6 alkoxy or -C 1-6 alkyl; or
  • R 13 and R 14 together with the carbon atom to which they are both attached form 3-6 membered carbocyclic ring, and each of the carbocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -NH 2 , -CN, -C 1-6 alkyl or -C 1-6 alkoxy;
  • R 2 is selected from hydrogen; deuterium; halogen; -OR 21 ; -NR 21 R 22 ; -CN; -SR 21 ; -SOR 21 ; -SO 2 R 21 ; -SO 2 NR 21 R 22 ; -C 1-6 alkyl; -C 2-6 alkenyl; -C 2-6 alkynyl; carboxyl; -NO 2 ; -COOR 21 ; -COR 21 ; -CONR 21 R 22 ; -NR 21 COR 22 ; -NR 21 CONR 21 R 22 ; -NR 21 SO 2 R 22 ; -NR 21 SO 2 NR 21 R 22 ; -OCONR 21 R 22 ; -POR 21 R 22 ; -C 5-6 aryl; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; -C 3-8 heterocyclic containing 1, 2, 3 or 4 heteroatoms selected from N, O
  • Each of R 21 and R 22 at each occurrence is independently selected from hydrogen; deuterium; -OH; NH 2 ; -CN; -C 1-6 alkyl; -C 1-6 alkoxy; -C 5-6 aryl; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; -C 1-6 alkylene-C 3-8 carbocyclic; or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -C 1-6 alkyl, -C 1-6 alkoxy, carboxyl, -SO 2 (C 1-6 alkyl) or -C 3-8 carbo
  • each of the heterocyclic ring at each occurrence can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium; halogen; -OH; oxo; -CN; -C 1-6 alkyl; -C 1-6 alkoxy; -SO 2 (C 1-6 alkyl) ; -CON (C 1-6 alkyl) 2 ; -SO 2 N (C 1-6 alkyl) 2 ; -NH 2 ; -NH (C 1-6 alkyl) ; -N (C 1-6 alkyl) 2 ; -C 3-6 heterocyclic containing 1 or 2 heteroatoms selected from N, O or S; or
  • R 23 and R 24 at each occurrence is independently selected from hydrogen, deuterium, halogen, -NH 2 , -C 1-6 alkoxy or -C 1-6 alkyl; or
  • R 23 and R 24 together with the carbon atom to which they are both attached form 3-6 membered carbocyclic ring, and each of the carbocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -NH 2 , -CN, -C 1-6 alkyl or -C 1-6 alkoxy;
  • A is selected from
  • Y 1 is selected from N or CR Y1 ;
  • Y 2 is selected from O, S, CR Y1 R Y2 or NR Y2 ;
  • R Y1 and R Y2 at each occurrence is independently selected from hydrogen, deuterium, halogen, -OH, NH 2 , -CN, -C 1-6 alkyl or -C 1-6 alkoxy;
  • Each of R 3 and R 4 at each occurrence is independently selected from hydrogen, deuterium, halogen, -CN, -SOR 5 , -SO 2 R 5 , -SO 2 NR 5 R 6 , -C 1-6 alkyl, -C 1-6 alkoxy, -COR 5 , -CONR 5 R 6 or -POR 5 R 6 ; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -NH 2 , -CN, -C 1-6 alkyl or -C 1-6 alkoxy;
  • Each of R 5 and R 6 at each occurrence is independently selected from hydrogen; deuterium; -OH; -NH 2 ; -CN; -C 1-6 alkyl; -C 1-6 alkoxy; -C 5-6 aryl; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; -C 1-6 alkylene-C 3-8 carbocyclic; or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -C 1-6 alkyl, -C 1-6 alkoxy, carboxyl, -SO 2 (C 1-6 alkyl) or -C 3-8 carb
  • each of the heterocyclic ring at each occurrence can further contains 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 , and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium; halogen; -OH; oxo; -CN; -C 1-6 alkyl; -C 1-6 alkoxy; -SO 2 (C 1-6 alkyl) ; -CON (C 1-6 alkyl) 2 ; -SO 2 N (C 1-6 alkyl) 2 ; -NH 2 ; -NH (C 1-6 alkyl) ; -N (C 1-6 alkyl) 2 ; -C 3-6 heterocyclic containing 1 or 2 heteroatoms selected from N, O or S; or
  • W 1 is selected from hydrogen; deuterium; halogen; -NH 2 ; -CN; -OH; -NO 2 ; carboxyl; -C 1-6 alkyl; -C 1-6 alkoxy; -C 1-6 alkylene-C 1-6 alkoxy; -C 5-10 aryl; -C 5-10 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; -C 3-8 heterocyclic containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted;
  • W 2 is selected from hydrogen; deuterium; halogen; -NH 2 ; -CN; -OH; -NO 2 ; carboxyl; -C 1-6 alkyl; -C 1-6 alkoxy; -C 5-10 aryl; -C 5-10 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; -C 3-8 heterocyclic containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted;
  • S in the formula I-2 indicates that the absolute configuration of the carbon that contacts with the W 1 , W 2 and Z is S configuration when the carbon is chiral carbon.
  • S in the formula II-2 indicates that the absolute configuration of the carbon that contacts with the W 1 , W 2 and Z is S configuration when the carbon is chiral carbon.
  • R in the formula III-1 indicates that the absolute configuration of the carbon that contacts with the W 1 , W 2 and Z is R configuration when the carbon is chiral carbon.
  • S in the formula III-2 indicates that the absolute configuration of the carbon that contacts with the W 1 , W 2 and Z is S configuration when the carbon is chiral carbon.
  • the compound is of formula IV:
  • the compound is of formula IV-1:
  • R in the formula IV-1 indicates that the absolute configuration of the carbon that contacts with the W 1 , W 2 and Z is R configuration when the carbon is chiral carbon.
  • the compound is of formula IV-2:
  • S in the formula IV-2 indicates that the absolute configuration of the carbon that contacts with the W 1 , W 2 and Z is S configuration when the carbon is chiral carbon.
  • R 1 is selected from hydrogen; deuterium; -SOR 11 ; -SO 2 R 11 ; -SO 2 NR 11 R 12 ; -C 1-6 alkyl; -COOR 11 ; -COR 11 ; -CONR 11 R 12 ; -POR 11 R 12 ; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S or SO 2 ; -C 3-8 heterocyclic containing 1, 2, 3 or 4 heteroatoms selected from N, O, S or SO 2 ; or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -C 1-6 alkyl, -C 1-6 alkoxy, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 al
  • Each of R 11 and R 12 at each occurrence is independently selected from hydrogen, deuterium, -C 1-6 alkyl, -C 1-6 alkylene-C 3-8 carbocyclic or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -SO 2 (C 1-6 alkyl) or -C 3-8 carbocyclic; or
  • each of the heterocyclic ring at each occurrence can further contains 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 , and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium; halogen; -OH; oxo; -CN; -C 1-6 alkyl; -C 1-6 alkoxy; -SO 2 (C 1-6 alkyl) ; -CON (C 1-6 alkyl) 2 ; -SO 2 N (C 1-6 alkyl) 2 ; -NH 2 ; -NH (C 1-6 alkyl) ; -N (C 1-6 alkyl) 2 ; -C 3-6 heterocyclic containing 1 or 2 heteroatoms selected from N, O or S; or -C
  • R 13 and R 14 at each occurrence is independently selected from hydrogen, deuterium or -C 1-6 alkyl; or
  • R 13 and R 14 together with the carbon atom to which they are both attached form 3-6 membered carbocyclic ring, and each of the carbocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3 or 4 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -NH 2 , -CN, -C 1-6 alkyl or -C 1-6 alkoxy;
  • n is selected from 0, 1, 2 or 3.
  • R 1 is selected from hydrogen; deuterium; -SOR 11 ; -SO 2 R 11 ; -SO 2 NR 11 R 12 ; -C 1-3 alkyl; -COOR 11 ; -COR 11 ; -CONR 11 R 12 ; -POR 11 R 12 ; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S or SO 2 ; -C 3-6 heterocyclic containing 1, 2, 3 or 4 heteroatoms selected from N, O, S or SO 2 ; or -C 3-6 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -C 1-3 alkyl, -C 1-3 alkoxy, -NH 2 , -NH (C 1-3 alkyl)
  • Each of R 11 and R 12 at each occurrence is independently selected from hydrogen, deuterium, -C 1-3 alkyl, -C 1-3 alkylene-C 3-6 carbocyclic or -C 3-6 carbocyclic, and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -CN, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , -C 1-3 alkyl, -C 1-3 alkoxy, -SO 2 (C 1-3 alkyl) or -C 3-6 carbocyclic; or
  • each of the heterocyclic ring at each occurrence can further contains 1, 2 or 3 heteroatoms selected from N, O or SO 2 , and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium; -F; -Cl; -Br; -OH; oxo; -CN; -C 1-3 alkyl; -C 1-3 alkoxy; -SO 2 (C 1-3 alkyl) ; -CON (C 1-3 alkyl) 2 ; -SO 2 N (C 1-3 alkyl) 2 ; -NH 2 ; -NH (C 1-3 alkyl) ; -N (C 1-3 alkyl) 2 ; -C 4-6 heterocyclic containing 1 heteroatoms selected from N or O;
  • R 13 and R 14 at each occurrence is independently selected from hydrogen, deuterium or -C 1-3 alkyl; or
  • R 13 and R 14 together with the carbon atom to which they are both attached form 3-6 membered carbocyclic ring, and each of the carbocyclic ring is independently optionally substituted with 1, 2, 3 or 4 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -NH 2 , -CN, -C 1-3 alkyl or -C 1-3 alkoxy;
  • n is selected from 0, 1, 2 or 3.
  • R 1 is selected from hydrogen; deuterium; -SOR 11 ; -SO 2 R 11 ; -SO 2 NR 11 R 12 ; methyl; ethyl; propyl; isopropyl; -COOR 11 ; -COR 11 ; -CONR 11 R 12 ; -POR 11 R 12 ; 5-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 6-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 3-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 4-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 5-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 6-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2
  • Each of R 11 and R 12 at each occurrence is independently selected from hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -methylene-3-membered carbocyclic, -methylene-4-membered carbocyclic, -methylene-5-membered carbocyclic, -methylene-6-membered carbocyclic, -ethylene-3-membered carbocyclic, -ethylene-4-membered carbocyclic, -ethylene-5-membered carbocyclic, -ethylene-6-membered carbocyclic, 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic or 6-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -CN, -
  • R 11 and R 12 together with the nitrogen atom to which they are both attached form 4 membered heterocyclic ring, 5 membered heterocyclic ring or 6 membered heterocyclic ring, and each of the heterocyclic ring at each occurrence can further contains 1 or 2 heteroatoms selected from N, O or SO 2 , and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -SO 2 CH 3 , -SO 2 CH 2 CH 3 , -SO 2 CH 2 CH 2 CH 3 , -SO 2 CH (CH 3 ) 2 , -CON (CH 3 ) 2 , -CON (CH 2
  • R 13 and R 14 at each occurrence is independently selected from hydrogen, deuterium, methyl, ethyl, propyl or isopropyl; or
  • R 13 and R 14 together with the carbon atom to which they are both attached form 3 membered carbocyclic ring, 4 membered carbocyclic ring, 5 membered carbocyclic ring or 6 membered carbocyclic ring, and each of carbocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3 or 4 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -NH 2 , -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy;
  • n is selected from 0, 1, 2 or 3.
  • R 1 is selected from hydrogen; deuterium; -SOR 11 ; -SO 2 R 11 ; -SO 2 NR 11 R 12 ; methyl; ethyl; propyl; isopropyl; -COOR 11 ; -COR 11 ; -CONR 11 R 12 ; -POR 11 R 12 ; 5-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 6-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; or 3-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy
  • Each of R 11 or R 12 at each occurrence is independently selected from hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -methylene-3-membered carbocyclic or 3-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -NH 2 , -NH (CH 3 ) , -N (CH 3 ) 2 , methyl, methoxy, -SO 2 CH 3 or 3-membered carbocyclic; or
  • R 11 and R 12 together with the nitrogen atom to which they are both attached form the heterocyclic selected from and the heterocyclic ring is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, oxo, -CN, methyl, methoxy, -SO 2 CH 3 , -CON (CH 3 ) 2 , -SO 2 N (CH 3 ) 2 , -NH 2 , -NH (CH 3 ) , -N (CH 3 ) 2 , -CH 2 D, -CHD 2 or -CD 3 ;
  • R 13 and R 14 at each occurrence is independently selected from hydrogen, deuterium, methyl, ethyl, propyl or isopropyl; or
  • R 13 and R 14 together with the carbon atom to which they are both attached form 3 membered carbocyclic ring, and the carbocyclic ring is independently optionally substituted with 1, 2, 3 or 4 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -OH, methyl, ethyl, propyl or isopropyl;
  • n is selected from 0 or 1.
  • R 1 is selected from hydrogen, deuterium, -SOCH 3 , -SOCH 2 CH 3 , SOCH 2 CH 2 CH 3 , -SOCH (CH 3 ) 2 , -SO 2 CH 3 , -SO 2 CD 3 , -SO 2 CH 2 CH 3 , -SO 2 CH 2 CH 2 CH 3 , -SO 2 CH (CH 3 ) 2 , SO 2 CH (CD 3 ) 2 , -SO 2 NH 2 , -SO 2 NH (CH 3 ) , -SO 2 N (CH 3 ) 2 , -SO 2 NH (CD 3 ) , -SO 2 N (CD 3 ) 2 , -SO 2 NH (CH 2 CH 3 ) , -SO 2 N (CH 2 CH 3 ) 2 , -SO 2 NH (CH 2 CH 3 ) , -SO 2 N (CH 2 CH 3 ) 2 , -SO 2 NH (CH 2 CH 3 ) 2 , -SO 2 N (CH
  • R 1 is selected from -SO 2 R 11 , -C 1-6 alkyl, or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -C 1-6 alkyl, -C 1-6 alkoxy, -NH 2 , -NH (C 1-6 alkyl) , or -N (C 1-6 alkyl) 2 ;
  • n is selected from 0, 1, 2, 3, 4, 5 or 6.
  • R 1 is selected from -SO 2 R 11 , -C 1-3 alkyl, or -C 3-6 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -C 1-3 alkyl, -C 1-3 alkoxy, -NH 2 , -NH (C 1-3 alkyl) or -N (C 1-3 alkyl) 2 ;
  • R 13 and R 14 at each occurrence is independently selected from hydrogen, deuterium or -C 1-3 alkyl;
  • n is selected from 0, 1, 2 or 3.
  • R 1 is selected from -SO 2 R 11 , methyl, ethyl, propyl, isopropyl, 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic or 6-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -NH 2 , -NH (CH 3 ) , -NH (CH 2 CH 3 ) , -NH (CH 2 CH 2 CH 3 ) , -NH (CH (CH 3 ) 2 ) , -N (CH 3 ) 2 , -N (CH 2 CH 3 ) 2
  • R 11 is selected from hydrogen, deuterium, methyl, ethyl, propyl or isopropyl;
  • n is selected from 0, 1, 2 or 3.
  • R 1 is selected from -SO 2 CH 3 , -SO 2 CD 3 , -SO 2 CH 2 CH 3 , -SO 2 CH 2 CH 2 CH 3 , -SO 2 CH (CH 3 ) 2 , -SO 2 CH (CD 3 ) 2 , -CH 3 , -CH 2 D, -CHF 2 , -CH 2 F, -CD 2 H, -CD 3 , -CF 3 , -CH 2 CH 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , -CH 2 CH 2 NH 2 , -CH 2 CH 2 NHCH 3 , -CH 2 CH 2 N (CH 3 ) 2 , -CH 2 CD 3 , -CH 2 CF 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 F, -CH 2 CH 2 CD 3 , -CH 2 CH 2 CH 2 F, -CH 2 CH 2 CD 3 , -CH 2 CH 2 CF 3 ,
  • R 1 is selected from -SO 2 CH 3 , -CH 3 , -CHF 2 , -CD 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CH 2 N (CH 3 ) 2 , -CH 2 CF 3 , -CH (CH 3 ) 2 ,
  • R 1 is -C 1-6 alkyl
  • R 1 is selected from methyl, ethyl, propyl or isopropyl.
  • R 1 is methyl
  • R 2 is selected from hydrogen; deuterium; halogen; -OR 21 ; -NR 21 R 22 ; -CN; -SR 21 ; -SOR 21 ; -SO 2 R 21 ; -SO 2 NR 21 R 22 ; -C 1-6 alkyl; -C 2-6 alkenyl; -COOR 21 ; -COR 21 ; -CONR 21 R 22 ; -NR 21 COR 22 ; -NR 21 SO 2 R 22 ; -POR 21 R 22 ; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S or SO 2 ; -C 3-8 heterocyclic containing 1, 2, 3 or 4 heteroatoms selected from N, O, S or SO 2 ; or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each substituents at each occurrence is independently selected from de
  • Each of R 21 and R 22 at each occurrence is independently selected from hydrogen, deuterium, -C 1-6 alkyl, -C 1-6 alkylene-C 3-8 carbocyclic or -C 3-8 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -C 1-6 alkyl, -C 1-6 alkoxy, -SO 2 (C 1-6 alkyl) or -C 3-8 carbocyclic; or
  • R 23 and R 24 at each occurrence is independently selected from hydrogen, deuterium or -C 1-6 alkyl; or
  • R 23 and R 24 together with the carbon atom to which they are both attached form 3-6 membered carbocyclic ring, and each of the carbocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3 or 4 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -NH 2 , -CN, -C 1-6 alkyl or -C 1-6 alkoxy;
  • n is selected from 0, 1, 2, 3, 4, 5 or 6.
  • R 2 is selected from hydrogen; deuterium; -F; -Cl; -Br; -OR 21 ; -NR 21 R 22 ; -CN; -SR 21 ; -SOR 21 ; -SO 2 R 21 ; -SO 2 NR 21 R 22 ; -C 1-3 alkyl; -C 2-3 alkenyl; -COOR 21 ; -COR 21 ; -CONR 21 R 22 ; -NR 21 COR 22 ; -NR 21 SO 2 R 22 ; -POR 21 R 22 ; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S or SO 2 ; -C 3-6 heterocyclic containing 1, 2, 3 or 4 heteroatoms selected from N, O, S or SO 2 ; or -C 3-6 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each substituents
  • Each of R 21 or R 22 at each occurrence is independently selected from hydrogen, deuterium, -C 1-3 alkyl, -C 1-3 alkylene-C 3-6 carbocyclic or -C 3-6 carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -CN, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , -C 1-3 alkyl, -C 1-3 alkoxy, -SO 2 (C 1-3 alkyl) or -C 3-6 carbocyclic; or
  • each of the heterocyclic ring at each occurrence can further contains 1, 2 or 3 heteroatoms selected from N, O or SO 2 , and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium; -F; -Cl; -Br; -OH; oxo; -CN; -C 1-3 alkyl; -C 1-3 alkoxy; -SO 2 (C 1-3 alkyl) ; -CON (C 1-3 alkyl) 2 ; -SO 2 N (C 1-3 alkyl) 2 ; -NH 2 ; -NH (C 1-3 alkyl) ; -N (C 1-3 alkyl) 2 ; -C 4-6 heterocyclic containing 1 heteroatoms selected from N or O; or
  • R 23 and R 24 at each occurrence is independently selected from hydrogen, deuterium or -C 1-3 alkyl; or
  • R 23 and R 24 together with the carbon atom to which they are both attached form 3-6 membered carbocyclic ring, and each of the carbocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3 or 4 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -OH, -NH 2 , -CN, -C 1-3 alkyl or -C 1-6 alkoxy;
  • n is selected from 0, 1, 2 or 3.
  • R 2 is selected from hydrogen; deuterium; -F; -Cl; -Br; -OR 21 ; -NR 21 R 22 ; -CN; -SR 21 ; -SOR 21 ; -SO 2 R 21 ; -SO 2 NR 21 R 22 ; methyl; ethyl; propyl; isopropyl; ethenyl; propenyl; -COOR 21 ; -COR 21 ; -CONR 21 R 22 ; -NR 21 COR 22 ; -NR 21 SO 2 R 22 ; -POR 21 R 22 ; 5-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 6-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 3-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 4-membered heterocyclic containing 1, 2 or 3
  • Each of R 21 or R 22 at each occurrence is independently selected from hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -methylene-3-membered carbocyclic, -methylene-4-membered carbocyclic, -methylene-5-membered carbocyclic, -methylene-6-membered carbocyclic, -ethylene-3-membered carbocyclic, -ethylene-4-membered carbocyclic, -ethylene-5-membered carbocyclic, -ethylene-6-membered carbocyclic, 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic or 6-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -CN, -
  • each of the heterocyclic ring at each occurrence can further contains 1 or 2 heteroatoms selected from N, O or SO 2 , and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -SO 2 CH 3 , -SO 2 CH 2 CH 3 , -SO 2 CH 2 CH 2 CH 3 , -SO 2 CH (CH 3 ) 2 , -CON (CH 3 ) 2 , -CON (CH 2 CH 3
  • R 23 and R 24 at each occurrence is independently selected from hydrogen, deuterium, methyl, ethyl, propyl or isopropyl; or
  • n is selected from 0, 1, 2 or 3.
  • R 2 is independently selected from hydrogen; deuterium; -F; -Cl; -Br; -OR 21 ; -NR 21 R 22 ; -CN; -SR 21 ; -SOR 21 ; -SO 2 R 21 ; -SO 2 NR 21 R 22 ; methyl; ethyl; propyl; isopropyl; ethenyl; -COOR 21 ; -COR 21 ; -CONR 21 R 22 ; -NR 21 COR 22 ; -NR 21 SO 2 R 22 ; -POR 21 R 22 ; 5-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; 6-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O, S or SO 2 ; or 3-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said
  • R 21 and R 22 together with the nitrogen atom to which they are both attached form the heterocyclic selected from and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, -SO 2 CH 3 , -CON (CH 3 ) 2 , -SO 2 N (CH 3 ) 2 , -NH 2 , -NH (CH 3 ) , -N (CH 3 ) 2 , -CH 2 D, -CHD 2 or -CD 3 ;
  • R 23 and R 24 at each occurrence is independently selected from hydrogen, deuterium, methyl, ethyl, propyl or isopropyl; or
  • R 23 and R 24 together with the carbon atom to which they are both attached form 3-membered carbocyclic ring, and the carbocyclic ring is independently optionally substituted with 1, 2, 3 or 4 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, -NH 2 , -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy;
  • R 21 or R 22 at each occurrence is independently selected from hydrogen, deuterium or -C 1-6 alkyl; or
  • R 21 and R 22 together with the nitrogen atom to which they are both attached form 4-membered heterocyclic ring, 5-membered heterocyclic ring, 6-membered heterocyclic ring, each of the heterocyclic ring at each occurrence can further contains 1 or 2 heteroatoms selected from N or O, and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, oxo, -C 1-3 alkyl, -NH (C 1-3 alkyl) or -C 4-6 heterocyclic containing 1 heteroatoms selected from N or O;
  • n is selected from 0, 1, 2 or 3.
  • R 2 is selected from hydrogen, deuterium, -F, -Cl, -Br, -NR 21 R 22 , -SO 2 R 21 , -SO 2 NR 21 R 22 , methyl, ethyl, propyl, isopropyl, -COOR 21 , -COR 21 , -CONR 21 R 22 , -NR 21 COR 22 , -NR 21 SO 2 R 22 , -POR 21 R 22 , 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic or 6-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, -OH, methyl, ethyl, propyl, isopropyl, methoxy, eth
  • each of the heterocyclic ring at each occurrence ring can further contains 1 heteroatoms selected from N or O, and each of the heterocyclic ring at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, oxo, methyl, ethyl, propyl, isopropyl, -NHCH 3 , -NHCH 2 CH 3 , -NHCH 2 CH 2 CH 3 , -NHCH (CH 3 ) 2 ,
  • n is selected from 0, 1, 2 or 3.
  • R 2 is selected from hydrogen, deuterium, -F, -Cl, -Br, -NH 2 , -NHCH 3 , -N (CH 3 ) 2 , -NHCD 3 , -N (CD 3 ) 2 , -NHCH 2 CH 3 , -N (CH 3 CH 2 ) 2 , -N (CH 3 ) (CH 3 CH 2 ) , -NHCH 2 CH 2 CH 3 , -N (CH 2 CH 2 CH 3 ) 2 , -NHCH (CH 3 ) 2 , -N (CH 3 ) (CH (CH 3 ) 2 ) , -N (CH (CH 3 ) 2 ) 2 , -NHCH 2 CF 3 , -SO 2 CH 3 , -SO 2 CD 3 , -SO 2 CH 2 CH 3 , -SO 2 CH 2 CH 3 , -SO 2 CH (CH 3 ) 2 , -SO 2 CH (CD 3 , -SO 2 CH
  • R 2 is selected from hydrogen, -Cl, -Br, -NH 2 , -SO 2 CH 3 , -SO 2 NH 2 , -SO 2 NHCH 3 , -SO 2 N (CH 3 ) 2 , -CH 3 , -COOH, -COOCH 3 , -CONH 2 , -CONHCH 3 , -CON (CH 3 ) 2 , -NHCOCH 3 , -NHSO 2 CH 3 , -PO (CH 3 ) 2 or
  • Each of R 23 and R 24 at each occurrence is -C 1-6 alkyl.
  • each of R 23 and R 24 at each occurrence is -C 1-3 alkyl.
  • each of R 3 and R 4 at each occurrence is independently selected from hydrogen, deuterium, halogen, -CN, -SOR 5 , -SO 2 R 5 , -SO 2 NH 2 , -SO 2 NHR 5 , -SO 2 NR 5 R 6 , -C 1-3 alkyl, -C 1-3 alkoxy, -COR 5 , -CONH 2 , -CONHR 5 , -CONR 5 R 6 , -P (O) H 2 , -P (O) HR 5 or -POR 5 R 6 ; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen or -OH;
  • Each of R 5 and R 6 at each occurrence is independently selected from deuterium; -C 1-3 alkyl; -C 5-6 aryl; -C 5-6 heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; or -C 3-6 carbocyclic, and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen, -C 1-3 alkyl or -C 1-3 alkoxy.
  • each of R 3 and R 4 at each occurrence is independently selected from hydrogen, deuterium, -F, -Cl, -Br, -CN, -SOR 5 , -SO 2 R 5 , -SO 2 NH 2 , -SO 2 NHR 5 , -SO 2 NR 5 R 6 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropyl, -CONH 2 , -CONHR 5 , -CONR 5 R 6 , -P (O) H 2 , -P (O) HR 5 or -POR 5 R 6 ; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br or -OH;
  • Each of R 5 and R 6 at each occurrence is independently selected from deuterium; methyl; ethyl; propyl; isopropyl; phenyl; 5-membered heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; 6-membered heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, SO or SO 2 ; 3-membered carbocyclic; 4-membered carbocyclic; 5-membered carbocyclic; or 6-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropyl.
  • each of R 3 and R 4 at each occurrence is independently selected from hydrogen, deuterium, -F, -Cl, -Br, -CN, -SOCH 3 , -SOCH 2 CH 3 , -SOCH 2 CH 2 CH 3 , -SOCH (CH 3 ) 2 , -SO 2 CH 3 , -SO 2 CH 2 CH 3 , -SO 2 CH 2 CH 2 CH 3 , -SO 2 CH (CH 3 ) 2 , -SO 2 NH 2 , -SO 2 NHCH 3 , -SO 2 NHCH 2 CH 3 , -SO 2 NHCH 2 CH 2 CH 3 , -SO 2 NHCH (CH 3 ) 2 , -SO 2 N (CH 3 ) 2 , -SO 2 N (CH 2 CH 3 ) 2 , -SO 2 N (CH 3 ) (CH 2 CH 3 ) 2 , -SO 2 N (CH 3 ) (CH 2 CH 3 ) 2 , -SO 2 N
  • each of R 3 and R 4 at each occurrence is independently selected from hydrogen, deuterium, -F, -Cl, -Br, -CN, -SOCH 3 , -SOCD 3 , -SOCH 2 CH 3 , -SOCH 2 CH 2 CH 3 , -SOCH (CH 3 ) 2 , -SO 2 CH 3 , -SO 2 CD 3 , -SO 2 CH 2 CH 3 , -SO 2 CH 2 CH 2 CH 3 , -SO 2 CH (CH 3 ) 2 , -SO 2 NH 2 , -SO 2 NHCH 3 , -SO 2 NHCD 3 , -SO 2 NHCH 2 CH 3 , -SO 2 NHCH 2 CH 2 CH 3 , -SO 2 NHCH (CH 3 ) 2 , -SO 2 N (CH 3 ) 2 , -SO 2 N (CD 3 ) 2 , -SO 2 N (CH 2 CH 3 ) 2 , -SO 2 N (CH
  • each of R 3 and R 4 at each occurrence is independently selected from -C 1-3 alkyl, -CONH 2 , -CONHR 5 or -CONR 5 R 6 ; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium or halogen;
  • Each of R 5 and R 6 at each occurrence is independently selected from -C 1-3 alkyl or -C 3-6 carbocyclic, and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, halogen or -C 1-3 alkyl.
  • each of R 3 and R 4 at each occurrence is independently selected from methyl, ethyl, propyl, isopropyl, -CONH 2 , -CONHR 5 or -CONR 5 R 6 ; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl or -Br;
  • Each of R 5 and R 6 at each occurrence is independently selected from methyl, ethyl, propyl, isopropyl, 3-membered carbocyclic, 4-membered carbocyclic, 5-membered carbocyclic or 6-membered carbocyclic, and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl, -Br, methyl, ethyl, propyl or isopropyl.
  • each of R 3 or R 4 at each occurrence is independently selected from -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH (CH 3 ) 2 , -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , -OCH (CH 3 ) 2 , -CONH 2 , -CONHCH 3 , -CONHCH 2 CH 3 , -CONHCH 2 CH 2 CH 3 , -CONHCH (CH 3 ) 2 , -CON (CH 3 ) 2 , -CON (CH 3 ) 2 , -CON (CH 2 CH 3 ) 2 , -CON (CH 3 ) (CH 2 CH 3 ) or -CON (CH 2 CH 2 CH 3 ) 2 ; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F
  • each of R 3 or R 4 at each occurrence is independently selected from -CH 3 , -CD 3 , -CH 2 CH 3 , -CD 2 CD 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CD 3 , -CH (CH 3 ) 2 , -CH (CD 3 ) 2 , -CONH 2 , -CONHCH 3 , -CONHCD 3 , -CONHCH 2 CH 3 , -CONHCD 2 CD 3 , -CONHCH 2 CH 2 CH 3 , -CONHCH (CH 3 ) 2 , -CON (CH 3 ) 2 , -CON (CH 3 ) 2 , -CON (CH 2 CH 3 ) 2 , -CON (CH 3 ) (CH 2 CH 3 ) or -CON (CH 2 CH 2 CH 3 ) 2 .
  • each of R 3 or R 4 at each occurrence is independently selected from -CH 3 , -CD 3 , -CONH 2 , -CONHCH 3 , -CONHCH 2 CH 3 ,
  • each of R 3 and R 4 at each occurrence is independently selected from methyl, ethyl, propyl or isopropyl; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium, -F, -Cl or -Br.
  • each of R 3 and R 4 at each occurrence is independently selected from methyl, ethyl, propyl or isopropyl; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently selected from deuterium or -F.
  • each of R 3 and R 4 at each occurrence is independently selected from -CH 3 , -CH 2 D, -CD 2 H, -CD 3 , -CF 3 , -CH 2 CH 3 , -CH 2 CD 3 , -CH 2 CF 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 F, -CH 2 CH 2 CD 3 , -CH 2 CH 2 CF 3 , -CH (CH 3 ) 2 , -CH (CH 3 ) (CD 3 ) , -CH (CF 3 ) 2 or -CH (CD 3 ) 2 .
  • each of R 3 and R 4 at each occurrence is selected from -C 1-3 alkyl or the -C 1-3 alkyl substituted with 1, 2, 3, 4, 5 or 6 deuterium.
  • each of R 3 and R 4 at each occurrence is selected from methyl, ethyl, propyl, isopropyl, methyl substituted with deuterium, ethyl substituted with deuterium, propyl substituted with deuterium or isopropyl substituted with deuterium.
  • W 1 is selected from hydrogen; deuterium; -F; -Cl; -NH 2 ; -CN; -OH; carboxyl; -C 1-6 alkyl; -C 1-6 alkoxy; -C 1-3 alkylene-C 1-3 alkoxy; phenyl; 5-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O; 6-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O; 3-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O; 4-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O; 5-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O; 6-membered heterocyclic containing 1, 2 or 3 heteroatoms selected from N, O; 3-membered carbocyclic; 4-membered carbocyclic; 5-membered carbocyclic; or 6-membered carbocyclic; and each
  • W 1 is selected from hydrogen; deuterium; -F; -Cl; -NH 2 ; -CN; -OH; methyl; ethyl; propyl; isopropyl; methoxy; ethoxy; propoxy; isopropoxy; -CH 2 OCH 3 ; -CH 2 CH 2 OCH 3 ; -CH 2 CH 2 OCH 2 CH 3 ; phenyl; 5-membered heteroaryl containing 1 or 2 heteroatoms selected from N or O; 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N or O; 5-membered heterocyclic containing 1 or 2 heteroatoms selected from N or O; 6-membered heterocyclic containing 1 or 2 heteroatoms selected from N or O; 5-membered carbocyclic; or 6-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents, and the said each of substituents at each occurrence is independently optionally substitute
  • W 1 is selected from hydrogen; deuterium; -F; methyl; ethyl; propyl; isopropyl; methoxy; -CH 2 OCH 3 ; -CH 2 CH 2 OCH 3 ; 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N or O; 5-membered heterocyclic containing 1 or 2 heteroatoms selected from N or O; 6-membered heterocyclic containing 1 or 2 heteroatoms selected from N or O; 5-membered carbocyclic; or 6-membered carbocyclic; and each of which at each occurrence is independently optionally substituted with deuterium or -F.
  • W 1 is selected from -CH 2 CH 2 CF 3 or
  • W 2 is selected from phenyl; 5-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O, or S; or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O or S; and each of which at each occurrence is independently optionally substituted with 1, 2 or 3 substituents, and the said each of substituents at each occurrence is selected from -F, -Cl, -Br, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.
  • W 2 is selected from and each of which at each occurrence is independently optionally substituted with 1, 2 or 3 substituents, and the said each of substituents at each occurrence is selected from -F, -Cl, methyl or methoxy.
  • W 2 is selected from and each of which at each occurrence is independently optionally substituted with 1, 2 or 3 substituents, and the said each of substituents at each occurrence is selected from -F, -Cl, methyl or methoxy.
  • W 2 is selected from and each of which at each occurrence is independently optionally substituted with 1, 2 or 3 substituents, and the said each of substituents at each occurrence is selected from -F, -Cl, methyl or methoxy.
  • W 2 is selected from and each of which at each occurrence is independently optionally substituted with 1, 2 or 3 substituents, and the said each of substituents at each occurrence is selected from -F, -Cl, methyl or methoxy.
  • W 2 is independently selected from:
  • Z is selected from hydrogen, deuterium, -F, -Cl, -OH, -C 1-3 alkyl or -C 1-3 alkoxy.
  • Z is selected from hydrogen, deuterium, -F, -Cl, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.
  • R 3 and R 4 at each occurrence is selected from -C 1-3 alkyl or -C 1-3 alkyl substituted with 1, 2, 3, 4, 5 or 6 deuterium;
  • W 1 is selected from -C 1-6 alkyl substituted with -F,
  • W 2 is selected from and each of which at each occurrence is independently optionally substituted with 1, 2 or 3 substituents, and the said each of substituents at each occurrence is selected from -F, -Cl, -Br, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy;
  • Z is selected from hydrogen.
  • R 1 is selected from methyl, ethyl, propyl or isopropyl
  • W 1 is selected from -CH 2 CH 2 CF 3 or
  • W 2 is selected from:
  • Each of R 3 and R 4 at each occurrence is independently selected from -CH 3 or -CD 3 .
  • the compound is:
  • the compounds further is:
  • the compounds further is:
  • a pharmaceutical composition comprising at least one compound of formula I, a pharmaceutically acceptable salt thereof or stereoisomer thereof of the present invention, and at least one pharmaceutically acceptable excipient.
  • the said compound in a weight ratio to the said excipient within the range from about 0.0001 to about 10. In some embodiments, wherein the said compound in a weight ratio to the said excipient within the range from about 0.0005 to about 0.25.
  • a method of treating a patient having a diseases or conditions related to bromodomain proteins comprising administering to the patient a therapeutically effective amount of at least one compound of formula I, a pharmaceutically acceptable salt thereof or stereoisomer thereof; or the pharmaceutical composition.
  • the diseases or conditions related to bromodomain proteins is solid tumor and/or blood tumor.
  • the solid tumor is selected from lung cancer, gastrointestinal cancer, colon cancer, rectal cancer, colorectal cancer and/or ovarian cancer
  • the blood tumor is selected from myeloma and/or leukemia.
  • the lung cancer contains non-small cell lung cancer and/or small cell lung cancer; the gastrointestinal cancer contains esophageal cancer; the leukemia contains acute myeloid leukemia (AML) ) and/or acute lymphocytic leukemia (ALL) ; the myeloma contains multiple myeloma.
  • AML acute myeloid leukemia
  • ALL acute lymphocytic leukemia
  • the compound of formula I a pharmaceutically acceptable salt thereof or stereoisomer thereof; or the pharmaceutical composition for use in the treatment of diseases or conditions related to bromodomain protein.
  • the diseases or conditions related to bromodomain proteins is solid tumor and/or blood tumor.
  • the solid tumor is selected from lung cancer, gastrointestinal cancer, colon cancer, rectal cancer, colorectal cancer and/or ovarian cancer; the blood tumor is selected from myeloma and/or leukemia.
  • the lung cancer contains non-small cell lung cancer and/or small cell lung cancer; the gastrointestinal cancer contains esophageal cancer; the leukemia contains acute myeloid leukemia (AML) ) and/or acute lymphocytic leukemia (ALL) ; the myeloma contains multiple myeloma.
  • AML acute myeloid leukemia
  • ALL acute lymphocytic leukemia
  • the compound of formula I a pharmaceutically acceptable salt thereof or stereoisomer thereof; or the pharmaceutical composition for the manufacture of a medicament for the treatment of diseases or conditions related to bromodomain protein.
  • the diseases or conditions related to bromodomain proteins is solid tumor and/or blood tumor.
  • the solid tumor is selected from lung cancer, gastrointestinal cancer, colon cancer, rectal cancer, colorectal cancer and/or ovarian cancer; the blood tumor is selected from myeloma and/or leukemia.
  • the lung cancer contains non-small cell lung cancer and/or small cell lung cancer;
  • the gastrointestinal cancer contains esophageal cancer;
  • the leukemia contains acute myeloid leukemia (AML) ) and/or acute lymphocytic leukemia (ALL) ;
  • the myeloma contains multiple myeloma.
  • halogen as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo.
  • the preferred halogen groups include F, Cl and Br.
  • alkyl includes saturated monovalent hydrocarbon radicals having straight or branched.
  • alkyl radicals include methyl, ethyl, propyl, isopropyl, cyclcopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclcobutyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclcopentyl, n-hexyl, 2-hexyl, 2-methylpentyl and cyclohexyl.
  • C 1-6 as in C 1-6 alkyl is defined to identify the group as having 1, 2, 3, 4, 5 or 6 carbon atoms in a linear or branched arrangement.
  • alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above.
  • methylene i.e., -CH 2 -
  • ethylene i.e., -CH 2 -CH 2 -or -CH (CH 3 ) -
  • propylene i.e., -CH 2 -CH 2 -CH 2 -, -CH (-CH 2 -CH 3 ) -or –CH 2 -CH (CH 3 ) -
  • alkenyl means a straight or branch-chained hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms in length.
  • C 2-6 alkenyl contains from 2 to 6 carbon atoms.
  • Alkenyl group include, but are not limited to, for example, ethenyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, hepetenyl, octenyl and the like.
  • alkynyl contains a straight-or branch-chained hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms in length.
  • C 2-6 alkynyl contains from 2 to 6 carbon atoms.
  • Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
  • alkoxy radicals are oxygen ethers formed from the previously described alkyl groups.
  • aryl refers to an unsubstituted or substituted mono-or polycyclic aromatic ring system containing carbon ring atoms.
  • the preferred aryls are mono cyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls. The most preferred aryl is phenyl.
  • heterocyclic refers to unsubstituted and substituted mono-or polycyclic non-aromatic ring system containing one or more heteroatoms.
  • Preferred heteroatoms include N, O, and S, including N-oxides, sulfur oxides, and dioxides.
  • the ring is three to eight membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, preferably one, two or three, are included within the present definition.
  • heterocyclic groups include, but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone and oxadiazolyl.
  • heteroaryl represents an aromatic ring system containing carbon (s) and at least one heteroatom.
  • Heteroaryl may be monocyclic or polycyclic, substituted or unsubstituted.
  • a monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms.
  • a polycyclic heteroaryl ring may contain fused, spiro or bridged ring junction, for example, bycyclic heteroaryl is a polycyclic heteroaryl.
  • Bicyclic heteroaryl rings may contain from 8 to 12 member atoms.
  • Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (cabons and heteroatoms) .
  • heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adeninyl, quinolinyl or isoquinolinyl.
  • Carbocyclic refers to a substituted or unsubstituted monocyclic, bicyclic or polycyclic non-aromatic saturated ring, which optionally includes an alkylene linker through which the cycloalkyl may be attached.
  • Examplary "cycloalkyl” groups includes but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and so on.
  • carboxyl refers to the group C (O) OH.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
  • the compounds of the present invention may also be present in the form of pharmaceutically acceptable salts.
  • the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts" .
  • the pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • the pharmaceutically acceptable acidic/anionic salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid.
  • organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic.
  • Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.
  • the present invention includes within its scope the prodrugs of the compounds of this invention.
  • such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs” , ed. H. Bundgaard, Elsevier, 1985.
  • the present invention includes compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
  • the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.
  • the present invention includes all stereoisomers of the compound and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
  • stereoisomer refers to an isomer in which atoms or groups of atoms in the molecule are connected to each other in the same order but differ in spatial arrangement, including conformational isomers and conformational isomers.
  • the configuration isomers include geometric isomers and optical isomers, and optical isomers mainly include enantiomers and diastereomers.
  • the invention includes all possible stereoisomers of the compound, in particular, when the carbon atom directly attached to W 1 , W 2 , Z in formula (I) is a chiral carbon, the present invention includes stereoisomers in which the in the formula (I) is “R” configuration, and stereoisomers in which the in the formula (I) is “S” configuration.
  • the stereoisomers encompassed by the present invention include:
  • R in the formulae I-1, II-1, III-1, IV-1 indicates that when the carbon atom bonded to W 1 , W 2 and Z is a chiral carbon, the absolute configuration of the chiral carbon is the R configuration.
  • S in the formulae I-2, II-2, III-2, IV-2 indicates that when the carbon atom bonded to W 1 , W 2 and Z is a chiral carbon, the absolute configuration of the chiral carbon is the S configuration.
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium and tritium.
  • the isotopes of hydrogen can be denoted as 1 H (hydrogen) , 2 H (deuterium) and 3 H (tritium) . They are also commonly denoted as D for deuterium and T for tritium.
  • CD 3 denotes a methyl group wherein all of the hydrogen atom are deuterium.
  • Isotopes of carbon include 13 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by prcesses analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent.
  • the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
  • the present invention includes any possible solvates and polymorphic forms.
  • a type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable.
  • water, ethanol, propanol, acetone or the like can be used.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
  • the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60%pure, more suitably at least 75%pure, especially at least 98%pure (%are on a weight for weight basis) .
  • compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds represented by Formula I or a prodrug or a metabolite or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous) .
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion.
  • the compound represented by Formula I or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt, of Formula I.
  • the compounds of Formula I or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid or gas.
  • solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • oral liquid preparations such as suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
  • oral solid preparations such as powders, capsules and tablets.
  • tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
  • a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 0.05 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about 0.0lmg to about 2g of the active ingredient, typically 0.01mg, 0.02mg, 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or l000mg.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
  • compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 0.05wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
  • the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
  • dosage levels on the order of from about 0.001mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions or alternatively about 0.05mg to about 7g per patient per day.
  • inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) may be effectively treated by the administration of from about 0.001 to 50mg of the compound per kilogram of body weight per day or alternatively about 0.05mg to about 3.5g per patient per day.
  • the compounds in the present invention can be synthesized in a number of ways well to one skilled in the art of organic synthesis described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods are not limited as those described below.
  • the references cited here are incorporated by reference in their entirety.
  • Suzuki coupling of pyrazole 1 with the aromatic heterocycle 2, such as 2, 5-dibromo-3-nitropyridine using a suitable coupling catalyst, such as Pd (dppf) Cl 2 at the present of a base, like K 3 PO 4 in THF/H 2 O (5: 1 volume ratio) can give the 3.
  • Cadogan reductive cyclization of 3 at the present of a phosphine reagent, such as 1, 2-bis (diphenylphosphino) ethane (DPPE) or triethyl phosphate P (OEt) 3 and solvent, such as 1, 2-dichlorobenze or 1, 2-dimethyl-benzene with heating can give the tricycle 4.
  • a phosphine reagent such as 1, 2-bis (diphenylphosphino) ethane (DPPE) or triethyl phosphate P (OEt) 3
  • solvent such as 1, 2-dichlorobenze or 1, 2-dimethyl-benzene with heating
  • the 7 can be generated from a reaction between 4 and an alkylating agent 6, where L is a leaving group such as a halide, mesylate or triflate, in the presence of a base, such as potassium carbonate.
  • Acoupling of 7 with 8 (where M is a suitable coupling partner, such as boronic acid, boronic ester or stannane ) by a Suzuki or Stille reaction can generate 9.
  • 9 is a racemate
  • chiral separation can provide enantiomerically pure products.
  • R 1 and R 2 can provide additional compounds of the invention.
  • R 1 when R 1 is a protecting group, it can be further functionalized after de-protecting; when R 2 is an ester, addition of a Grignard reagent or alky lithium can generate tertiary alcohols.
  • the ester could instead be hydrolyzed using, for example, potassium hydroxide to give a carboxylic acid, which could be further functionalized using alky amines;
  • R 2 when R 2 is a -H, it can be replaced by a halogen, for example -Br, through a halogenation reaction using a reagent like NBS and can be further functionalized through a reaction, such as Buchwall, Mitszunobu or Stille reaction.
  • a heterocyclic aromatic 10 can be directly coupled to 7 (prepared as in Scheme 1) via palladium-mediated C-H activation to afford compound 9.
  • heterocyclic aromatic 10 can be deprotonated with a strong base such as n-BuLi and transmetallated to zinc or tin reagent to afford compound 8 which can be coupled by a Negishi or Stille reaction to 7 (prepared as in Scheme 1) at the present of a suitable palladium catalyst to afford compounds 9. This is illustrated in Scheme 3.
  • the crude compound was purified using a reverse phase chromatography eluting with 40 ⁇ 50 %MeCN in H 2 O to afford the racemic compound (52 g, 61 %yield) , which was separated by chiral prep SFC to give Enantiomer a1, (R) - (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methanol (25.1 g, 29.6 %yield) and Enantiomer b1, (S) - (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methanol (25.3 g, 29.7 %) .
  • Chiral Chromatography Report: RT 12.25 min (Column: Chiralpak AY-H (ADH0CE-VC001) 0.46 ⁇ 25 cm; Mobile Phase: 90/10/0.1 Hexane/EtOH/DEA; Flow: 1.0 mL/min) .
  • Chiral Chromatography Report: RT 14.023 min (Column: YMC, Chiral ART-amylose-C Neo (5 ⁇ m, 250 ⁇ 4.6mm; Mobile Phase: 90/10/0.1 Hexane/EtOH/TFA; Flow: 1.0 mL/min) .
  • Chiral Chromatography Report: RT 13.57 min (Column: Chiralpak AY-H (ADH0CE-VC001) 0.46 ⁇ 25 cm; Mobile Phase: 90/10/0.1 Hexane/EtOH/DEA; Flow: 1.0 mL/min) .
  • Chiral Chromatography Report: RT 12.760 min (Column: YMC, Chiral ART-amylose-C Neo (5 ⁇ m, 250 ⁇ 4.6mm; Mobile Phase: 90/10/0.1 Hexane/EtOH/TFA; Flow: 1.0 mL/min) .
  • Step 2 Methyl 6-bromo-1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 Methyl (S) -6-bromo-1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 5 (S) -2- (6- (3, 5-dimethylisoxazol-4-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 (R) - (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methanol ( “Enantiomer a1” ) and
  • Chiral Chromatography Report: RT 12.25 min (Column: Chiralpak AY-H (ADH0CE-VC001) 0.46 ⁇ 25 cm; Mobile Phase: 90/10/0.1 Hexane/EtOH/DEA; Flow: 1.0 mL/min) .
  • Chiral Chromatography Report: RT 14.023 min (Column: YMC, Chiral ART-amylose-C Neo (5 ⁇ m, 250 ⁇ 4.6mm; Mobile Phase: 90/10/0.1 Hexane/EtOH/TFA; Flow: 1.0 mL/min) .
  • Chiral Chromatography Report: RT 13.57 min (Column: Chiralpak AY-H (ADH0CE-VC001) 0.46 ⁇ 25 cm; Mobile Phase: 90/10/0.1 Hexane/EtOH/DEA; Flow: 1.0 mL/min) .
  • Chiral Chromatography Report: RT 12.760 min (Column: YMC, Chiral ART-amylose-C Neo (5 ⁇ m, 250 ⁇ 4.6mm; Mobile Phase: 90/10/0.1 Hexane/EtOH/TFA; Flow: 1.0 mL/min) .
  • Step 3 (S) -Methyl 6- (3, 5-dimethylisoxazol-4-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 4 (S) -2- (6- (3, 5-dimethylisoxazol-4-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 Methyl 6-bromo-1-methyl-4- (4, 4, 4-trifluoro-1-phenylbutyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (4, 4, 4-trifluoro-1-phenylbutyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • the mixture was degassed under vacuum, backfilled with nitrogen gas, and this sequence was repeated three times.
  • the resulting mixture was stirred at 110 °C for 2 h.
  • the reaction mixture was cooled to r.t., diluted with water (50 mL) and extracted with EtOAc (3 ⁇ 50 mL) . After separation, the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step 3 2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (4, 4, 4-trifluoro-1-phenylbutyl) -1, 4 -dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • MeMgBr (1M in THF, 3.2 mL, 3.20 mmol) was slowly added to a solution of methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (4, 4, 4-trifluoro-1-phenylbutyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate (176 mg, 0.34 mmol ) in dry THF (10 ml) at -30 °C under N 2 over 1 min. After addition, the reaction was warmed to r.t. and stirred for 2 hr. The reaction was quenched with sat.
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (4, 4, 4-trifluoro-1- (3-fluoropyridin-2-yl) butyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 1 Methyl 6-bromo-1-methyl-4- ( (3-methylpyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 (S) -6-bromo-1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • Step 4 (S) -6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • the mixture was vacuumed, backfilled with N 2 and this process was repeated three times.
  • the resulting mixture was stirred at 85 °C for 3 h and then cooled to room temperature.
  • the reaction mixture was poured into water and extracted with EtOAc (100 mL) .
  • the organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step 5 (S) -3-bromo-6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • N-bromosuccinimide (0.62 g, 3.48 mmol) was added in small batches to a solution of (S) -6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine (0.63 g, 1.43 mmol) in THF (20 mL) and water (10 mL) at room temperature over 10 min. After addition, the reaction was stirred at room temperature for 2 h. The reaction was quenched with sat.
  • Step 6 (S) -1- (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) ethan-1-one
  • Step 6 (S) -2- (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 (S) -methyl 6-bromo-4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 (S) -Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate ( “Compound 7-2” )
  • the mixture was vacuumed, backfilled with N 2 and this process was repeated three times.
  • the resulting mixture was stirred at 85 °C for 3 h and then cooled to room temperature.
  • the reaction mixture was poured into water and extracted with EtOAc (50 mL) .
  • the organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step 3 (S) -2- (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 Methyl 6-bromo-1-methyl-4- ( (3-methylpyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (3, 5-dimethylisoxazol-4-yl) -1-methyl-4- ( (3-methylpyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 2- (6- (3, 5-Dimethylisoxazol-4-yl) -1-methyl-4- ( (3-methylpyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 Methyl 6-bromo-1-methyl-4- ( (tetrahydro-2H-pyran-4-yl) (o-tolyl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (3, 5-dimethylisoxazol-4-yl) -1-methyl-4- ( (tetrahydro-2H-pyran-4-yl) (o-tolyl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 2- (6- (3, 5-dimethylisoxazol-4-yl) -1-methyl-4- ( (tetrahydro-2H-pyran-4-yl) (o-tolyl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 Methyl 6-bromo-1-methyl-4- (4, 4, 4-trifluoro-1- (oxazol-4-yl) butyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (4, 4, 4-trifluoro-1- (oxazol-4-yl) butyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 2- (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (4, 4, 4-trifluoro-1- (oxazol-4-yl) butyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 Methyl 6-bromo-1-methyl-4- (4, 4, 4-trifluoro-1- (3-methylpyridin-2-yl) butyl) -1, 4-dihydro pyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (4, 4, 4-trifluoro-1- (3-methylpyridin-2-yl) butyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 2- (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (4, 4, 4-trifluoro-1- (3-methylpyridin-2-yl) butyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 2 Methyl 6-bromo-1-methyl-4- ( (2-methyloxazol-4-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- ( (2-methyloxazol-4-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • the mixture was degassed and flushed with nitrogen for three times and stirred at 110 °C for 16 h.
  • the mixture was cooled to room temperature, diluted with water (50 mL) and extracted with EtOAc (3 ⁇ 50 mL) .
  • the combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and the filtrated was concentrated under reduced pressure.
  • Step 4 2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- ( (2-methyloxazol-4-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 3 Methyl 5- (5-bromo-3-nitro-2-pyridyl) -1- (2-trimethylsilylethoxymethyl) pyrazole-3-carboxylate
  • the mixture was purged with a N 2 stream for 3 min , attached with a condenser, then warmed to 38 °C and stirred for 3 h under a N 2 atmosphere.
  • the reaction mixture was cooled to room temperature, poured into water (300 mL) and extracted with EtOAc (3 ⁇ 200 mL) .
  • the collected organic phases were washed with brine, dried over anhydrous sodium sulfate, and concentrated on a rotary evaporator.
  • Step 4 Methyl 6-bromo-1- ( (2- (trimethylsilyl) ethoxy) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 5 (S) -Methyl 6-bromo-4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1- ( (2- (trimethylsilyl) ethoxy) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 6 (S) -Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1- ( (2- (trimethylsilyl) ethoxy) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 7 (S) -Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 8 (S) -2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 (S) -Methyl 4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -6- (1-methyl-4- (methyl-d3) -1H-1, 2, 3-triazol-5-yl) -1- ( (2- (trimethylsilyl) ethoxy) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • the mixture was purged with a N 2 stream for 3 min, attached with a condenser, then warmed to 110 °C and stirred for 16 hunder a N 2 atmosphere.
  • the reaction mixture was cooled to room temperature, poured into water (30 mL) and extracted with EtOAc (3x20 mL) .
  • the collected organic phases were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • Step 2 (S) -Methyl 4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -6- (1-methyl-4-(methyl-d3) -1H-1, 2, 3-triazol-5-yl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 (S) -Methyl 4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1- (methyl-d3) -6- (1-methyl-4- (methyl-d3) -1H-1, 2, 3-triazol-5-yl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • reaction mixture was slowly warmed to 60 °C and continued to stir for 2 h.
  • the reaction was quenched with 10 mL HCl (1N) and extracted with EtOAc (10 mL) . After separation, the organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step 4 (S) -2- (4- ( (3-Fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1- (methyl-d3) -6- (1-methyl-4- (methyl-d3) -1H-1, 2, 3-triazol-5-yl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • reaction mixture was cooled to 0 °C in an ice-water bath, followed by dropwise addition of 1.5 mL MeMgBr (3M in THF, 4.5 mmol) under N 2 atmosphere. Then the reaction mixture was slowly warmed to room temperature and continued stirring for 1 h. The reaction was quenched with sat. NH 4 Cl. The reaction mixture was concentrated under reduced pressure.
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylic acid
  • Step 4 6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carbonyl chloride
  • Step 5 6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -N, N, 1-trimethyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxamide
  • Step1 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxamide
  • Step1 6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -N, 1-dimethyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxamide
  • Step1 2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 2 3- (2-Azidopropan-2-yl) -6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • Step 3 2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-amine
  • Step2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- ( (4-methylpyridin-3-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step3 2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (4-methylpyridin-3-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 (S) -Methyl 4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-6- (1-methyl-4- (methyl-d3) -1H-1, 2, 3-triazol-5-yl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • the mixture was vacuumed, backfilled with N 2 and this process was repeated three times.
  • the resulting mixture was stirred at 85 °C for 3 hr and then cooled to room temperature.
  • the reaction mixture was poured into water and extracted with EtOAc (100 mL) .
  • the organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step 2 (S) -2- (4- ( (3-Fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-6- (1-methyl-4- (methyl-d3) -1H-1, 2, 3-triazol-5-yl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 Methyl 6-bromo-4- ( (3-fluoropyridin-4-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-4-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-4-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 Methyl 6-bromo-4- ( (4-methoxypyridin-3-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1- methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (4-methoxypyridin-3-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 1 Methyl 6-bromo-4- ( (3-methoxypyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-methoxypyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step3 2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-methoxypyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 Methyl 6-bromo-4- (1- (4-fluoro-2, 6-dimethylphenyl) ethyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- (1- (4-fluoro-2, 6-dimethylphenyl) ethyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 2- (6- (1, 4-Dimethyl-1H-1, 2, 3-triazol-5-yl) -4- (1- (4-fluoro-2, 6-dimethylphenyl) ethyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step1 (S) -6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-amine
  • the mixture was stirred 110 °C for 3 days.
  • the mixture was poured into water (50 mL) and extracted with EtOAc (150 mL) .
  • the collected organic layer was washed with brine (50 mL) , dried by Na 2 SO 4 , and concentrated on a rotary vacuum evaporator.
  • Step2 (S) -N- (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) methanesulfonamide
  • Step 1 (R) -Methyl 6-bromo-4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 (R) -Methyl 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • the mixture was vacuumed, backfilled with N 2 and this process was repeated three times.
  • the resulting mixture was stirred at 85 °C for 3 h and then cooled to room temperature.
  • the reaction mixture was poured into water and extracted with EtOAc (30 mL) .
  • the organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step 3 (R) -2- (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step 1 (R) -Methyl 6-bromo-4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 2 (R) -Methyl 6- (3, 5-dimethylisoxazol-4-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step 3 (R) -2- (6- (3, 5-dimethylisoxazol-4-yl) -4- ( (3-fluoropyridin-2-yl) (tetrahydro-2H-pyran-4-yl) methyl) -1-methyl-1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) propan-2-ol
  • Step1 methyl 6-bromo-1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine-3-carboxylate
  • Step2 (6-bromo-1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) methanol
  • Step3 6-bromo-3- (bromomethyl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • Step4 6-bromo-1-methyl-3- ( (4-methylpiperazin-1-yl) methyl) -4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • Step5 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-3- ( (4-methylpiperazin-1-yl) methyl) -4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • the mixture was purged with N 2 for 2min, and stirred at 110°C for 16 hr .
  • the reaction mixture was cooled to r.t , poured into water and extracted with EtOAc (100 mL) . After separation, the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step1 6-bromo-1-methyl-3- ( (methylsulfonyl) methyl) -4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • Step2 6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-3- ( (methylsulfonyl) methyl) -4- (phenyl (tet rahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridine
  • the mixture was purged with N 2 for 2min, stirred at 110 °C for 20 hr .
  • the reaction mixture was cooled to r.t, poured into water and extracted with EtOAc (100 mL) . After separation, the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step1 4- ( (6-bromo-1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) methyl) morpholine
  • Step2 4- ( (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) methyl) morpholine
  • the mixture was purged with N 2 for 2 min, stirred at 110 °C for 20 hr .
  • the reaction mixture was cooled to r.t., poured into water and extracted with EtOAc (100 mL) . After separation, the organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated.
  • Step1 N- (6- (1, 4-dimethyl-1H-1, 2, 3-triazol-5-yl) -1-methyl-4- (phenyl (tetrahydro-2H-pyran-4-yl) methyl) -1, 4-dihydropyrazolo [3', 4': 4, 5] pyrrolo [3, 2-b] pyridin-3-yl) -N- (methylsulfonyl) acetamide
  • the BRD4 (BD1) biochemical binding assay was performed by Sundia MediTech Co. Ltd. in 384-well white plate (OptiPlate-384, PerkinElmer) using HTRF technology.
  • Table 3 shows that the compound of the present invention has a very strong affinity with BRD4 (BD1) .
  • MV-4-11 cell proliferation analysis was conducted by the MTS (3- (4, 5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium, inner salt) assay. Briefly, MV-4-11 cells will be cultured in IMDM (Iscove’s Modified Dubecco’s Medium) medium supplemented with 10% (v/v) FBS (fetal bovine serum) , under the temperature of 37 °C, 5%CO 2 and 95%humidity. The cells will be harvested respectively during the logarithmic growth period and counted with hemocytometer. The cell viability is over 90%by trypan blue exclusion.
  • IMDM Iscove’s Modified Dubecco’s Medium
  • FBS fetal bovine serum
  • Table 4 shows that the compound of the present invention has an excellent inhibitory effect on leukemia cell MV-4-11.
  • the compound of the present invention has a very excellent inhibitory effect on various cancer cells such as lung cancer cells, other leukemia cancer cells, myeloma cancer cells, esophageal cancer cells, and ovarian cancer cells
  • lung cancer cells include but are not limited to NCI-H526 lung cancer cells, NCI-H146 lung cancer cells, NCI-H820 lung cancer cells, DMS53 lung cancer cells, NCI-H446 lung cancer cells and the like
  • the leukemia cancer cells include but are not limited to NB4 leukemia cancer cells, JJN-3 leukemia cancer cells, Kasumi-1 leukemia cancer cells, OCI-AML3 leukemia cancer cells, THP-1 leukemia cancer cells and the like
  • the myeloma cancer cells include but are not limited to NCI-H929 myeloma cancer cells, KMS-11 myeloma cancer cells and the like
  • esophageal cancer cells include but are not limited to COLO-680N esophageal

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des composés tricycliques utilisés en tant qu'inhibiteurs de bromodomaines et extra-terminaux (BET) représentés par la formule I, leur synthèse et leur utilisation pour le traitement de maladies. Plus particulièrement, la présente invention concerne des dérivés hétérocycliques fusionnés utiles en tant qu'inhibiteurs de BET, des procédés de production de tels composés et des méthodes de traitement de maladies et d'affections dans lesquelles l'inhibition d'un ou de plusieurs bromodomaines BET présente un avantage.
PCT/CN2019/084601 2018-06-25 2019-04-26 Composés tricycliques WO2020001152A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
BR112020026337-0A BR112020026337A2 (pt) 2018-06-25 2019-04-26 Compostos tricíclicos
KR1020217002239A KR102600391B1 (ko) 2018-06-25 2019-04-26 삼중고리형 화합물
CN202210507765.9A CN115109061A (zh) 2018-06-25 2019-04-26 三环化合物
JP2020572516A JP7168245B2 (ja) 2018-06-25 2019-04-26 三環式化合物
EA202190103A EA202190103A1 (ru) 2018-06-25 2019-04-26 Трициклические соединения
CN201980041760.8A CN112513041B (zh) 2018-06-25 2019-04-26 三环化合物
AU2019295983A AU2019295983B2 (en) 2018-06-25 2019-04-26 Tricyclic compounds
SG11202012819YA SG11202012819YA (en) 2018-06-25 2019-04-26 Tricyclic compounds
CA3104927A CA3104927C (fr) 2018-06-25 2019-04-26 Composes tricycliques
EP19826294.1A EP3814352A4 (fr) 2018-06-25 2019-04-26 Composés tricycliques
MX2020014111A MX2020014111A (es) 2018-06-25 2019-04-26 Compuestos triciclicos.
PH12020552210A PH12020552210A1 (en) 2018-06-25 2020-12-17 Tricyclic compounds
US17/129,983 US20210179617A1 (en) 2018-06-25 2020-12-22 Tricyclic compounds
ZA2021/00237A ZA202100237B (en) 2018-06-25 2021-01-13 Tricyclic compounds
AU2021290208A AU2021290208B2 (en) 2018-06-25 2021-12-20 Tricyclic compounds
US17/561,381 US11466005B2 (en) 2018-06-25 2021-12-23 Tricyclic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/092542 2018-06-25
CN2018092542 2018-06-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/129,983 Continuation US20210179617A1 (en) 2018-06-25 2020-12-22 Tricyclic compounds

Publications (1)

Publication Number Publication Date
WO2020001152A1 true WO2020001152A1 (fr) 2020-01-02

Family

ID=68986044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/084601 WO2020001152A1 (fr) 2018-06-25 2019-04-26 Composés tricycliques

Country Status (15)

Country Link
US (2) US20210179617A1 (fr)
EP (1) EP3814352A4 (fr)
JP (1) JP7168245B2 (fr)
KR (1) KR102600391B1 (fr)
CN (2) CN115109061A (fr)
AU (2) AU2019295983B2 (fr)
BR (1) BR112020026337A2 (fr)
CA (1) CA3104927C (fr)
EA (1) EA202190103A1 (fr)
MX (1) MX2020014111A (fr)
PH (1) PH12020552210A1 (fr)
SG (1) SG11202012819YA (fr)
TW (1) TWI705965B (fr)
WO (1) WO2020001152A1 (fr)
ZA (1) ZA202100237B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022156757A1 (fr) * 2021-01-22 2022-07-28 Jingrui Biopharma Co., Ltd. Composés tricycliques en tant qu'agents anticancéreux
WO2024099441A1 (fr) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Dégradeur de protéine à bromodomaines et domaine extra-terminal (bet)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012819YA (en) * 2018-06-25 2021-01-28 Jacobio Pharmaceuticals Co Ltd Tricyclic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164596A1 (fr) * 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Inhibiteurs de bromodomaines bet et méthodes thérapeutiques les utilisant
WO2016183118A1 (fr) * 2015-05-12 2016-11-17 Bristol-Myers Squibb Company Composés tricycliques utilisés en tant qu'agents anticancéreux
WO2017124936A1 (fr) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 Dérivé de carboline servant comme inhibiteur de bromodomaines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103848818B (zh) * 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
SG11201605097SA (en) * 2013-12-24 2016-07-28 Bristol Myers Squibb Co Tricyclic compounds as anticancer agents
WO2016183114A1 (fr) * 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Composés tricycliques utilisés en tant qu'agents anticancéreux
US10174024B2 (en) * 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
EP3412669A4 (fr) 2016-02-05 2019-09-04 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Composé tricyclique pour inhibiteur de protéine contenant un bromodomaine et préparation, composition pharmaceutique et son utilisation
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
WO2019080941A1 (fr) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. Nouveaux composés tricycliques
SG11202012819YA (en) * 2018-06-25 2021-01-28 Jacobio Pharmaceuticals Co Ltd Tricyclic compounds
CN113544129A (zh) * 2019-04-04 2021-10-22 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164596A1 (fr) * 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Inhibiteurs de bromodomaines bet et méthodes thérapeutiques les utilisant
WO2016183118A1 (fr) * 2015-05-12 2016-11-17 Bristol-Myers Squibb Company Composés tricycliques utilisés en tant qu'agents anticancéreux
WO2017124936A1 (fr) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 Dérivé de carboline servant comme inhibiteur de bromodomaines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022156757A1 (fr) * 2021-01-22 2022-07-28 Jingrui Biopharma Co., Ltd. Composés tricycliques en tant qu'agents anticancéreux
WO2024099441A1 (fr) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Dégradeur de protéine à bromodomaines et domaine extra-terminal (bet)

Also Published As

Publication number Publication date
CN112513041B (zh) 2022-05-10
JP2021530455A (ja) 2021-11-11
CA3104927C (fr) 2023-09-12
US20220119390A1 (en) 2022-04-21
AU2021290208A1 (en) 2022-01-20
CN112513041A (zh) 2021-03-16
KR102600391B1 (ko) 2023-11-10
MX2020014111A (es) 2021-06-15
AU2021290208B2 (en) 2023-09-21
SG11202012819YA (en) 2021-01-28
EA202190103A1 (ru) 2021-03-29
US11466005B2 (en) 2022-10-11
TW202017928A (zh) 2020-05-16
CA3104927A1 (fr) 2020-01-02
CN115109061A (zh) 2022-09-27
ZA202100237B (en) 2022-10-26
TWI705965B (zh) 2020-10-01
PH12020552210A1 (en) 2021-06-28
AU2019295983A1 (en) 2021-02-11
EP3814352A1 (fr) 2021-05-05
US20210179617A1 (en) 2021-06-17
JP7168245B2 (ja) 2022-11-09
EP3814352A4 (fr) 2022-03-30
BR112020026337A2 (pt) 2021-03-30
AU2019295983B2 (en) 2021-09-30
KR20210045981A (ko) 2021-04-27

Similar Documents

Publication Publication Date Title
CN113286794B (zh) Kras突变蛋白抑制剂
KR102041442B1 (ko) 중수소화된 디아미노피리미딘 화합물 및 이 화합물을 함유하는 약물 조성물
WO2022105855A1 (fr) Inhibiteurs de kras g12d
WO2022188729A1 (fr) Dérivés cycliques fusionnés utiles en tant qu'inhibiteurs de kras g12d
WO2021057832A1 (fr) Inhibiteur de protéine mutante kras
KR102388312B1 (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
US11866433B2 (en) Diarylthiohydantoin compound as androgen receptor antagonist
AU2019295983B2 (en) Tricyclic compounds
JP2015523350A (ja) Ｒｓウイルス抗ウイルス薬としての、ベンゾイミダゾールによって置換された新規１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
AU2021209744B2 (en) Novel heterocyclic compounds useful as Aurora A selective inhibitors
TW201728577A (zh) 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物
WO2019094319A1 (fr) Dérivés de pyrrolopyrazine à utiliser en tant qu'inhibiteurs de l'intégrine alpha v
CA3216163A1 (fr) Composes carboxy-benzimidazoles modulateurs du glp-1r
JP2019518032A (ja) Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
KR20220097466A (ko) 이미다졸리디논류 화합물 및 이들의 제조방법과 용도
WO2024008068A1 (fr) Inhibiteurs de protéine mutante k-ras
WO2023246777A1 (fr) Inhibiteurs de protéine mutante k-ras
EA042760B1 (ru) Трициклические соединения
CN117751117A (zh) Sarm1酶活性抑制剂及其应用
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19826294

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3104927

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020572516

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020026337

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019295983

Country of ref document: AU

Date of ref document: 20190426

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112020026337

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201222